首页 正文

First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer

{{output}}
Fluoropyrimidine+cisplatin/oxaliplatin+trastuzumab therapy is recommended for the first-line treatment of HER2-positive metastatic gastric adenocarcinoma. However, there is no comprehensive study on which platinum-based treatment should be preferred. This stud... ...